Simões Marta Filipa, Valente Emília, Gómez M José Rodríguez, Anes Elsa, Constantino Luís
iMed.UL, Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.
Eur J Pharm Sci. 2009 Jun 28;37(3-4):257-63. doi: 10.1016/j.ejps.2009.02.012. Epub 2009 Mar 6.
Pyrazinamide (PZA) is active against M. tuberculosis and is a first line agent for the treatment of human tuberculosis. PZA is itself a prodrug that requires activation by a pyrazinamidase to form its active metabolite pyrazinoic acid (POA). Since the specificity of cleavage is dependent on a single bacterial enzyme, resistance to PZA is often found in tuberculosis patients. Esters of POA have been proposed in the past as alternatives to PZA however the most promising compounds were rapidly degraded in the presence of serum. In order to obtain compounds that could survive during the transport phase, we synthesized lipophilic ester and amide POA derivatives, studied their activity against M. tuberculosis, their stability in plasma and rat liver homogenate and also their activation by a mycobacterial homogenate. The new lipophilic ester prodrugs were found to be active in concentrations 10-fold lower than those needed for PZA to kill sensitive M. tuberculosis and also have a suitable stability in the presence of plasma. Amides of POA although more stable in plasma have lower activity. The reason can probably be found in the rate of activation of both types of prodrugs; while esters are easily activated by mycobacterial esterases, amides are resistant to activation and are not transformed into POA at a suitable rate.
吡嗪酰胺(PZA)对结核分枝杆菌有活性,是治疗人类结核病的一线药物。PZA本身是一种前药,需要通过吡嗪酰胺酶激活才能形成其活性代谢产物吡嗪酸(POA)。由于裂解的特异性取决于单一细菌酶,结核病患者中经常发现对PZA耐药。过去曾有人提出POA的酯类作为PZA的替代品,但最有前景的化合物在血清存在下会迅速降解。为了获得在转运阶段能够存活的化合物,我们合成了亲脂性酯和酰胺类POA衍生物,研究了它们对结核分枝杆菌的活性、在血浆和大鼠肝匀浆中的稳定性以及它们被分枝杆菌匀浆激活的情况。发现新的亲脂性酯前药的活性浓度比PZA杀死敏感结核分枝杆菌所需的浓度低10倍,并且在血浆存在下具有合适的稳定性。POA的酰胺类虽然在血浆中更稳定,但活性较低。原因可能在于两种前药的激活速率;酯类很容易被分枝杆菌酯酶激活,而酰胺类则对激活有抗性,不能以合适的速率转化为POA。